Pharmaceutical Opioids For Chronic Non-cancer Pain: Evaluating Health Outcomes And Economic Impact Over Five Years
Funder
National Health and Medical Research Council
Funding Amount
$775,922.00
Summary
Chronic non-cancer pain (CNCP) is a major contributor to disability. Increased opioid prescribing for CNCP has produced concern about dependence and overdose in the absence on data on its long-term effectiveness. Novel statistical methods will test causal relationships over 5 years between treatment, outcomes, and costs on 1,514 CNCP patients prescribed opioids. We will answer critical questions on 5-year outcomes, and whether, and for whom, opioids and other clinical interventions reduce costs.
Optimising Care For Patients Diagnosed With Pancreatic Cancer: A Prospective Cohort Study
Funder
National Health and Medical Research Council
Funding Amount
$1,399,839.00
Summary
There is evidence from previous research in Queensland and NSW that elements of care provided to patients with pancreatic cancer are sub-optimal. We aim to improve compliance with evidence-based guidelines in Victoria and NSW by collecting high quality data, providing reports to hospitals benchmarking their performance against peers and working with health services to reduce variation. Making sure care known to improve practice is being delivered is as important as developing new targeted thera
Preventing Hospital Readmission In A Regional Australian Hospital Setting
Funder
National Health and Medical Research Council
Funding Amount
$565,695.00
Summary
Hospitals face high levels of emergency presentations and demand for inpatient care particularly for Aboriginal Australian people from remote communities. Readmissions lead to overcrowded emergency departments and poorer patient outcomes. We will evaluate the efficacy of a multidimensional case-based management intervention linking hospital and primary health in a regional Australian hospital with the aim of reducing hospital readmission and improving patient outcomes.
Glucocorticoid Resistance In Paediatric Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$394,721.00
Summary
Glucocorticoids are among the most effective drugs used in the treatment of many haematological malignancies, including leukaemia, lymphoma and multiple myeloma. However, the development of tumour cell resistance to these drugs remains a significant problem, and clinically relevant mechanisms of glucocorticoid resistance remain poorly understood. This project aims to define mechanisms of resistance to glucocorticoids and develop new drugs to reverse resistance.
Targeting Microtubules To Overcome Chemoresistance In Pancreatic Cancer
Funder
National Health and Medical Research Council
Funding Amount
$594,336.00
Summary
Pancreatic cancer is a devastating disease with a dismal prognosis because it is extremely resistant to chemotherapy agents. We plan to examine the expression of proteins called microtubules in pancreatic cancer and assess their role in drug resistance. It is anticipated that the findings of these studies will lead to the development of effective approaches to sensitise the cancer cells to chemotherapy agents.
Activation Of BMP4 Signalling To Inhibit Breast Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$748,742.00
Summary
The spread of cancer cells to other organs is a common cause of breast cancer-related death in women. Current therapies for advanced breast cancer are often palliative since the secondary tumours become resistant to the chemotherapy. Here, we are using preclinical models of advanced breast cancer to develop a treatment that should be effective in patients with secondary tumours and should reduce the risk of dying of this disease.
Prevention Of Multi-drug Resistant Tuberculosis In A High Prevalence Setting: ‘Connecting The DOTS’ In Vietnam
Funder
National Health and Medical Research Council
Funding Amount
$3,382,020.00
Summary
The close contacts of people with multi-drug resistant tuberculosis (MDR-TB) have a high risk of developing the disease. The V-QUIN MDR-TB Trial will evaluate the effectiveness of an oral antibiotic (levofloxacin) in preventing drug resistant TB among infected household contacts of TB patients. Household contacts from 10 Provinces in Vietnam will be randomly allocated to receive six-months of either levofloxacin or a placebo, and then followed for two years to see if they develop tuberculosis.
Pathways To Prevention: The Effectiveness Of Universal And Selective Prevention In Altering Developmental Pathways To Alcohol And Cannabis Related Harms In Young Adults
Funder
National Health and Medical Research Council
Funding Amount
$465,967.00
Summary
This project will assess the potential long-term benefits for young Australians of two school-based drug prevention programs (Climate Schools and Preventure) compared to drug education as usual. This world-first study will inform national and international policy by evaluating whether prevention programs delivered in Year 8 are effective in reducing alcohol and cannabis related harms, including risk of aggression and violence, over the high risk period during young adulthood (ages 18-20).
Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Heparin-induced Thrombocytopenia And Thrombosis: Better Understanding Of Pathogenesis And Improving Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$653,137.00
Summary
Heparin, a widely used drug, can cause an adverse effect which results in a fall of the platelet count and the development of serious thrombosis. This drug complication is mediated by an immune mechanism. This proposal aims to provide a better understanding of the disease mechanism. It also aims to develop a new test that will improve the diagnosis, and to produce a novel drug that will effectively suppress the immune reaction and improve the treatment.